Patents Represented by Attorney Kathryn A. Seese

Find this attorney in the Justia Lawyer Directory

  • DNA encoding a fusion receptor for oncostatin M and leukemia inhibitory factor
    Patent number: 5426048
    Abstract: A receptor protein comprising a gp130 polypeptide linked to a single-chain leukemia inhibitory factor receptor (LIF-R) polypeptide is capable of binding both oncostatin M and leukemia inhibitory factor (LIF). The receptor protein binds LIF with greater affinity than does the single-chain LIF-R polypeptide alone. The receptor may be produced as a fusion protein in recombinant cells. The gp130 polypeptide binds oncostatin M, but with lower affinity than does the inventive receptor protein.
    Type: Grant
    Filed: August 31, 1993
    Date of Patent: June 20, 1995
    Assignee: Immunex Corporation
    Inventor: David P. Gearing
  • DNA encoding leukemia inhibitory factor receptors
    Patent number: 5284755
    Abstract: Leukemia inhibitory factor receptor (LIF-R) proteins, DNAs and expression vectors encoding LIF-R, and processes for producing LIF-R as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: September 11, 1992
    Date of Patent: February 8, 1994
    Assignee: Immunex Corporation
    Inventors: David P. Gearing, M. Patricia Beckmann
  • Interleukin-7 receptors
    Patent number: 5264416
    Abstract: Mammalian Interleukin-7 receptor proteins, DNAs and expression vectors encoding mammalian IL-7 receptors, and processes for producing mammalian IL-7 receptors as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: June 1, 1992
    Date of Patent: November 23, 1993
    Assignee: Immunex Corporation
    Inventors: Linda S. Park, Raymond G. Goodwin
  • Receptor for oncostatin M and leukemia inhibitory factor
    Patent number: 5262522
    Abstract: A receptor protein comprising a gp130 polypeptide linked to a single-chain leukemia inhibitory factor receptor (LIF-R) polypeptide is capable of binding both oncostatin M and leukemia inhibitory factor (LIF). The receptor protein binds LIF with greater affinity than does the single-chain LIF-R polypeptide alone. The receptor may be produced as a fusion protein in recombinant cells. The gp130 polypeptide binds oncostatin M, but with lower affinity than does the inventive receptor protein.
    Type: Grant
    Filed: November 22, 1991
    Date of Patent: November 16, 1993
    Assignee: Immunex Corporation
    Inventor: David P. Gearing
  • DNA encoding interleukin-7 receptors and methods of use
    Patent number: 5194375
    Abstract: Mammalian Interleukin-7 receptor proteins, DNAs and expression vectors encoding mammalian IL-7 receptors, and processes for producing mammalian IL-7 receptors as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: May 21, 1990
    Date of Patent: March 16, 1993
    Assignee: Immunex Corporation
    Inventors: Linda S. Park, Raymond G. Goodwin
  • Process for preparing bovine interleukin-I.beta.
    Patent number: 5108911
    Abstract: A process for preparing bovine interleukin I.beta. (bIL-1.beta.) by culturing a microbial host transformed by a vector containing a DNA sequence encoding bIL-1.beta. under conditions suitable for the expression of bIL-1.beta. and recovering bIL-1.beta..
    Type: Grant
    Filed: August 11, 1989
    Date of Patent: April 28, 1992
    Assignee: Immunex Corporation
    Inventors: Douglas P. Cerretti, Brian S. Davis, Charles R. Maliszewski
  • Process for isolation and radiolabeling of pharmaceuticals with isotopes of astatine
    Patent number: 5102651
    Abstract: A process for recovering At-211 from a target and simultaneously producing an At-211-labeled radiopharmaceutical agent involves introducing volatilized At-211, produced by dry distillation of an irradiated Bi-209 target, into a solution containing a compound that binds the At-211 to form an At-211-labeled radiopharmaceutical agent. The radiopharmaceutical agent may have therapeutic use as is, or may be attached to a targeting protein such as an antibody prior to administation to a patient.
    Type: Grant
    Filed: December 29, 1989
    Date of Patent: April 7, 1992
    Assignee: NeoRx Corporation
    Inventors: Daniel S. Wilbur, Stephen W. Hadley
  • Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
    Patent number: 5057301
    Abstract: Modified cellular substrates are used as linking groups that are recognized as cellular substrates by intracellular metabolic enzymes. The linking groups function to attach a ligand, such as a drug or radionuclide, to a targeting protein, such as an antibody or antibody fragment. The false substrate structure of the linking groups causes increased cellular retention of the linking group/ligand conjugate because the enzymes used for catabolism of the substrate are inhibited by the false substrate structure of the linking group.
    Type: Grant
    Filed: April 6, 1988
    Date of Patent: October 15, 1991
    Assignee: NeoRx Corporation
    Inventors: Daniel S. Wilbur, Mark D. Hylarides
  • Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
    Patent number: 5021556
    Abstract: Chelating compounds which comprise one or more sulfur atoms and are to be radiolabeled with metal radionuclides to form the corresponding chelates are disclosed. The chelating compounds comprise thioacetal or hemithioacetal sulfur protecting groups which are displaced during the radiolabeling reaction, which is conducted at acidic pH, such that bonds form between said sulfur atoms and said radionuclide. The resulting metal radionuclide chelates have diagnostic and therapeutic medical uses.
    Type: Grant
    Filed: July 1, 1988
    Date of Patent: June 4, 1991
    Assignee: NeoRx Corporation
    Inventor: Ananthachari Srinivasan